Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation

NCT04366232 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped investigator decision

Conditions

Covid-19

Interventions

DRUG: Anakinra alone (stages 2b/3)
DRUG: Anakinra and Ruxolitinib (overcome stage 3)
OTHER: Standard of care

Sponsor

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

Collaborators

[object Object]
[object Object]